Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Weighted Average) (2016 - 2025)

Altimmune (ALT) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $82.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 15.63% to $82.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $82.2 million, a 15.63% increase, with the full-year FY2024 number at $71.0 million, up 33.35% from a year prior.
  • Shares Outstanding (Weighted Average) was $82.2 million for Q3 2025 at Altimmune, up from $81.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $82.2 million in Q3 2025 to a low of $38.9 million in Q1 2021.
  • A 5-year average of $56.7 million and a median of $50.4 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 157.53% in 2021, then grew 6.7% in 2025.
  • Altimmune's Shares Outstanding (Weighted Average) stood at $41.3 million in 2021, then increased by 13.67% to $46.9 million in 2022, then rose by 13.47% to $53.2 million in 2023, then soared by 33.35% to $71.0 million in 2024, then increased by 15.77% to $82.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Shares Outstanding (Weighted Average) are $82.2 million (Q3 2025), $81.5 million (Q2 2025), and $75.5 million (Q1 2025).